NRx Pharmaceuticals completed the acquisition of Dura Medical, which added a revenue-generating network of precision psychiatry clinics on Florida’s West Coast. The company also reported a Q3 EPS of -$0.27, a wider loss than -$0.15 in the same quarter last year. In December, NRx Pharmaceuticals eliminated all of its $5.4 million in balance-sheet debt by converting it into equity with no additional warrants, strengthening its capital structure ahead of regulatory milestones. Additionally, NRx Pharmaceuticals secured $7.8 million in debt financing from Universal Capital, LLC to support further HOPE Clinic acquisitions in Florida. The company achieved several R&D milestones, including the FDA receiving and deeming substantially complete its ANDA for KETAFREE, a preservative-free IV ketamine formulation, and receiving FDA Fast Track Designation for NRX-100 for treating suicidal ideation in depression. NRx Pharmaceuticals reported real-world ketamine treatment outcomes from more than 70,000 patients, showing rapid reductions in depression and suicidality, supporting its clinical development and regulatory strategy for NRX-100 and related therapies.